Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval
Follows Recent Approval For Amgen’s Bekemv Eculizumab Biosimilar
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.
You may also be interested in...
Samsung Bioepis has taken to five its number of IPR challenges to Alexion’s US Soliris intellectual property portfolio, filing two simultaneously.
As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.